Format

Send to

Choose Destination
Graefes Arch Clin Exp Ophthalmol. 2009 Apr;247(4):535-9. doi: 10.1007/s00417-008-0964-7. Epub 2008 Oct 22.

AlphaCor keratoprosthesis: postoperative development of six patients.

Author information

1
Eye Department of Schlosspark-Klinik, Berlin, Germany. so.holak@gmx.de

Abstract

PURPOSE:

AlphaCor (Argus Biomedical Pty. Ltd., Perth, Australia) is an artificial, soft, one-piece keratoprosthesis (KPro) indicated for severe corneal conditions not treatable by a donor graft. To evaluate the efficacy and visual restoring of six patients with complete corneal opacification and deep neovascularizations treated with AlphaCor.

METHODS:

A retrospective review of six patients with a history of corneal opacification treated with keratoprosthesis surgery. AlphaCor synthetic cornea was implanted into the corneal stroma. During the follow-up time, slit-lamp and ultrasound examinations, best corrected visual acuity (BCVA), and intraocular pressure measurements were performed.

RESULTS:

Six eyes with corneal scarring and vascularizations in three to four quadrants of six patients to years of age underwent a keratoprosthesis procedure. The follow-up time was 13-36 months; mean 23 months. The operation procedure was not limited by severe complications. The preoperative BCVA was hand movement to light perception. The postoperative BCVA ranged between 20/200 and 80/100. Intraocular pressure was controlled in all cases. Three patients developed a melting of the anterior corneal lamella. The keratoprosthesis had to be explanted (15-34 months after implantation) and was replaced by a donor cornea.

CONCLUSIONS:

Further evaluation is needed to evaluate the role of AlphaCor as a keratoprosthesis.

PMID:
18941767
DOI:
10.1007/s00417-008-0964-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center